Taking advantage of a large assortment of chemical inhibitors produced by the pharmaceutical industry as potential drugs, Howard Hughes Medical Institute researchers have synthesized and characterized a panel of compounds that may...
See more »
Taking advantage of a large assortment of chemical inhibitors produced by the pharmaceutical industry as potential drugs, Howard Hughes Medical Institute researchers have synthesized and characterized a panel of compounds that may lead to new treatment strategies for targeting glioblastoma, a common type of brain tumor that usually thwarts treatment. The compounds have also revealed new information about insulin signaling, and could be a powerful tool to evaluate cellular enzymes as potential targets for drug design. The work is detailed in two papers published in the journals Cell and Cancer Cell. HHMI investigator Kevan M. Shokat at the University of California, San Francisco, is the senior author on the Cell paper, published on-line April 27, 2006, which describes a pharmacological map of the family of enzymes known as PI3-kinases. Zachary A. Knight, an HHMI predoctoral fellow in Shokat's lab, is the first author of the study, which was conducted in collaboration with colleagues from UCSF. The second paper, published in the May 15, 2006, issue of the journal Cancer Cell, describes the effects of inhibiting these kinases in glioblastoma cells. Shokat and Knight collaborated on the Cancer Cell paper with senior author William A. Weiss at UCSF.
See less »
Kaboodle will send you a newsletter and updates from your friends. You can unsubscribe at any time. Kaboodle does not sell or share your email address or personal information with anyone.
Kaboodle requires all users to provide their real date of birth as both a safety precaution and as a means
of preserving the integrity of the site. You will be able to hide this information from your profile if you wish.
Added by 1 people